Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : Ferring Pharmaceuticals A/S
Homme Max 99 ans
Ferring Pharmaceuticals A/S
MAJ Il y a 5 ans
A randomised, parallel arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of prostate size reduction in prostate cancer patients of intermediate-to-high risk, who require neoadjuvant hormone therapy prior to radiotherapy (curative intent)
To demonstrate that the mean percentage reduction in prostate volume with degarelix is non-inferior to goserelin plus bicalutamide, based on a trans-rectal ultrasound scan (TRUS) at 12 weeks (Visit 5=...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Ferring Pharmaceuticals A/S
MAJ Il y a 5 ans
A randomised, open-label, assessor-blind, parallel groups, multicentre trial comparing the efficacy of MENOPUR versus recombinant FSH in controlled ovarian stimulation following a GnRH antagonist protocol and single embryo transfer
To compare MENOPUR and a recombinant FSH preparation with respect to pregnancy rates in women undergoing controlled ovarian stimulation following a GnRH antagonist protocol
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Ferring Pharmaceuticals A/S
MAJ Il y a 5 ans
A controlled, assessor-blind, parallel groups, multicentre, multinational trial evaluating the immunogenicity of FE 999049 in repeated cycles of controlled ovarian stimulation in women undergoing an assisted reproductive technology programme
To evaluate the immunogenicity of FE 999049 and GONAL-F based on the presence of anti-FSH antibodies and their neutralising capacity in women undergoing repeated controlled ovarian stimulation cycles
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Ferring Pharmaceuticals A/S
MAJ Il y a 5 ans
Estudio randomizado, doble ciego, de grupos paralelos, controlado con placebo, multicéntrico en donantes de oocitos que evalúa los efectos del barusiban, un antagonista selectivo de la oxitocina, sobre las contracciones uterinas el día que se transfiere el embrión al útero
Evaluar los efectos del barusiban comparados con placebo sobre las contracciones uterinas el día de la transferencia del embrión
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Ferring Pharmaceuticals A/S
MAJ Il y a 5 ans
A single-centre, open-label, randomised explorative pharmacokinetic/pharmacodynamic study of the gonadotropin-releasing hormone receptor antagonist degarelix (FE 200486) in patients with benign prostatic hyperplasia
To explore the pharmakokinetic/pharmacodynamic relationships at different doses of degarelix in benign prostatic hyperplasia (BPH) patients and to select doses and dosing regime for Phase II efficacy ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Ferring Pharmaceuticals A/S
MAJ Il y a 5 ans
An Open-Label, Multi-Centre, Randomised Parallel Group Comparison of Efficacy and Safety of Degarelix Three-Month Depot in Three Different Dosing Regimens of 240 mg (40 mg/mL) and 240 mg (60 mg/mL) in Patients with Prostate Cancer Requiring Androgen Ablation Therapy
•To demonstrate that the efficacy in achieving and maintaining testosterone castration levels (<=0.5 ng/mL) in prostate cancer patients treated up to either 12 or 13 months is at least 80%.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Ferring Pharmaceuticals A/S
MAJ Il y a 5 ans
An Open-Label, Multi-Centre, Randomised Parallel-Group Study, Investigating Efficacy and Safety of Different Degarelix Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Ablation Therapy
To demonstrate efficacy of degarelix in achieving and maintaining testosterone suppression at castrate levels (≤0.5 ng/mL) during one year of treatment in prostate cancer patients.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Ferring Pharmaceuticals A/S
MAJ Il y a 5 ans
An Open-label, Multi-Centre, Randomized, Parallel-group Study, Investigating the Efficacy and Safety of Degarelix One Month Dosing Regimens; 160 mg (40 mg/ml) and 80 mg (20mg/ml), in Comparison to LUPRON DEPOT® 7.5 mg in Patients with Prostate Cancer Requiring Androgen Ablation Therapy
Primary objective: •To demonstrate non-inferiority with respect to the proportion of patients achieving and maintaining testosterone suppression to castrate levels using a degarelix dosing regimen co...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Homme Max 99 ans
Ferring Pharmaceuticals A/S
MAJ Il y a 5 ans
A randomised, parallel-arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of reduction in International Prostate Symptom Score (IPSS), in patients with lower urinary tract symptoms (LUTS) secondary to locally advanced prostate cancer
To demonstrate that LUTS relief with degarelix is non-inferior to goserelin plus bicalutamide, based on a reduction in IPSS at 12 weeks as compared to baseline.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Ferring Pharmaceuticals A/S
MAJ Il y a 5 ans
Ensayo clínico para evaluar la efectividad de degarelix en ciclos de reproducción asistida
? To evaluate the synchrony of the follicle cohort at the start of stimulation associated with a mid-luteal injection of degarelix compared to placebo ? To describe the endometrial receptivity associ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
1
2
3
4
Suivant